Diversification in the boardroom improves the quality of board performance, encourages objectivity, and expands the quality of debate and decision making. Biopharmaceutical industry boardrooms are making progress, but still have work to do.
- Small Startup Going For A Big Play In Obesity
- A View From The Co-Chair Of Israel’s Biopharma Industry Trade Organization
- Leveraging Fractional Expertise to Drive Project Success and Cost Savings
- Examining The Growth Of Biopharma In Developing Countries
- Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
- What The Emerging Science Tells Us About Treating Obesity
- Exploring Functional Uses Of AI In Life Sciences
- Where Are They Now? Novo Nordisk
COMPANIES TO WATCH
-
![Kristine Ball Headshot 2023]( "Companies To Watch: Antiva Biosciences")
Companies To Watch: Antiva BiosciencesAntiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
![Robert Fallon, President & CEO, Promontory Tx]( "Companies to Watch: Promontory Therapeutics")
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
![Chris Hoyt_Companies To Watch_Jan]( "Companies To Watch: KeifeRx")
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
-
![CtW_Freya Bioscieneces _450x300]( "Companies To Watch: Freya Biosciences")
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
WHERE ARE THEY NOW
-
![WATN_Novo Nordisk]( "Where Are They Now? Novo Nordisk")
Where Are They Now? Novo NordiskIn a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
-
![Gyo Sagara LSL image]( "Where Are They Now? Ono Pharmaceuticals")
Where Are They Now? Ono PharmaceuticalsOno Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
-
![Vivek Ramaswamy]( "Where Are They Now? Roivant")
Where Are They Now? Roivant"Where Are They Now?" looks back, and forward, at companies and executives previously covered in Life Science Leader magazine.
SPOTLIGHT
Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.
LIFE SCIENCE LEADER CONTENT COLLECTIONS
2023 CMO & CRO AWARDS EDITION
